Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
164.50B
Market cap164.50B
Price-Earnings ratio
10.52
Price-Earnings ratio10.52
Dividend yield
3.36%
Dividend yield3.36%
Average volume
16.85M
Average volume16.85M
High today
$38.20
High today$38.20
Low today
$37.89
Low today$37.89
Open price
$36.41
Open price$36.41
Volume
808.42K
Volume808.42K
52 Week high
$81.44
52 Week high$81.44
52 Week low
$35.12
52 Week low$35.12

NVO News

Simply Wall St 51m
Hims & Hers Health Is Down 6.1% After Expanding GLP-1 Access With Novo Nordisk Collaboration

In late March 2026, Hims & Hers Health announced a renewed collaboration with Novo Nordisk, adding a broad range of FDA-approved GLP-1 medications, including We...

Hims & Hers Health Is Down 6.1% After Expanding GLP-1 Access With Novo Nordisk Collaboration
Simply Wall St 3h
Has Novo Nordisk Fallen Too Far After Recent Pharma Sector Headlines

If you are wondering whether Novo Nordisk's current share price lines up with its fundamentals, this article walks through the key valuation angles that matter...

Has Novo Nordisk Fallen Too Far After Recent Pharma Sector Headlines
MarketWatch 3h
A high dose of Wegovy will cost $50 less than Zepbound

Novo Nordisk has launched the high-dose version of its GLP-1 injection at a price that’s $50 lower than the one for Eli Lilly’s competing drug. For patients pa...

A high dose of Wegovy will cost $50 less than Zepbound

Analyst ratings

61%

of 36 ratings
Buy
30.6%
Hold
61.1%
Sell
8.3%

More NVO News

Barron's 16h
The $190 Billion ‘Diabesity’ Market Is Set to Explode. Lilly and Novo Face These Stock Catalysts.

Healthcare The $190 Billion ‘Diabesity’ Market Is Set to Explode. Lilly and Novo Face These Stock Catalysts. In this article LLY NVO HIMS NOVO.B AMGN Eli Lilly’...

The $190 Billion ‘Diabesity’ Market Is Set to Explode. Lilly and Novo Face These Stock Catalysts.
TipRanks 23h
Novo Nordisk Stock Slips despite Milestone in Obesity Race with Eli Lilly

Novo Nordisk’s (NVO) shares edged lower on Tuesday morning despite its latest move to regain ground from archrival Eli Lilly (LLY). The Danish drug-making giant...

TipRanks 23h
Novo Nordisk says higher dose Wegovy injection available nationwide

Novo Nordisk (NVO) announced its higher dose Wegovy injection is available now in the U.S. nationwide. “This advancement builds on the many offerings for patien...

The Wall Street Journal 1d
Novo Nordisk Launches Higher-Dose Wegovy Weight-Loss Shot in U.S.

Prior to the launch of Wegovy HD, the highest available injectable dose was 2.4 milligrams of semaglutide. Hannah Beier/Reuters Novo Nordisk NOVO.B -0.70 %decr...

Novo Nordisk Launches Higher-Dose Wegovy Weight-Loss Shot in U.S.
TipRanks 1d
Novo Nordisk Updates Progress on 2026 DKK 15 Billion Share Buyback

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

CNBC 1d
Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment

Key Points Novo Nordisk's new Wegovy GLP-1 pill appears to be expanding the obesity treatment market, drawing in new patients rather than converting existing on...

Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
Simply Wall St 1d
Hims & Hers Health Valuation Check As Novo Nordisk GLP 1 Partnership Reopens Growth Path

Hims & Hers Health (HIMS) has restarted its collaboration with Novo Nordisk, bringing FDA-approved GLP-1 drugs like Wegovy and Ozempic back to its platform alon...

Hims & Hers Health Valuation Check As Novo Nordisk GLP 1 Partnership Reopens Growth Path

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.